Biogen Inc. (BVMF:BIIB34)

Market Cap	154.11B +24.4%
Revenue (ttm)	54.48B +2.2%
Net Income	7.12B -20.8%
EPS	48.42 -21.4%
Shares Out	n/a
PE Ratio	21.64
Forward PE	13.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	90
Average Volume	56
Open	160.80
Previous Close	162.00
Day's Range	160.32 - 165.01
52-Week Range	110.07 - 169.32
Beta	0.16
RSI	59.27
Earnings Date	Feb 6, 2026

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1978
• Employees: 7,605
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: BIIB34

Financial Performance

In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.

Financial numbers in USD